Translational and clinical studies of target-based cancer therapy.
The increasing number of negative trials in cancer treatment has prompted a systematic re-evaluation of target-based drugs. It is our impression that the sensitivity of current clinical trial methodology is inadequate to demonstrate the effectiveness of target-based drugs, in terms of tumor shrinkage, delay in progression, or improved survival. Enrichment of sensitive populations, based on the data from translational studies, is essential for a better understanding of the role of novel therapies in cancer. Translational and clinical studies are key to the identification and maximization of benefit of target-based therapy
Saijo
Nagahiro
N
National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Nishio
Kazuto
K
Tamura
Tomohide
T
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004341:Drug Evaluation; D006801:Humans; D008967:Molecular Biology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*
D000970:Antineoplastic Agents